Risk factor
Negligible price volatility
Profitability factor
Very low or no dividends
About
Tonghua Dongbao Pharmaceutical Co., Ltd. is a Chinese enterprise primarily engaged in the research, development, manufacturing, and commercialization of pharmaceutical products. These therapeutics are designed to address diabetes and various cardiovascular conditions within the Chinese market. Its operations are structured across two distinct divisions: pharmaceuticals and building materials. The company's extensive pharmaceutical portfolio features prominent insulin analogues, including insulin glargine, insulin aspart, and insulin lispro. Furthermore, it offers a range of antidiabetic medications, oral hypoglycemic drugs, and medical devices such as Gan Shulin pens and blood glucose meters. Tonghua Dongbao also maintains a strategic partnership with Adocia. Established in 1985, the company is headquartered in Tonghua, China.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, 'cheap' on EV/EBIT